CN102985420B - 细胞色素p450抑制剂及其用途 - Google Patents

细胞色素p450抑制剂及其用途 Download PDF

Info

Publication number
CN102985420B
CN102985420B CN201180034394.7A CN201180034394A CN102985420B CN 102985420 B CN102985420 B CN 102985420B CN 201180034394 A CN201180034394 A CN 201180034394A CN 102985420 B CN102985420 B CN 102985420B
Authority
CN
China
Prior art keywords
alkyl
bases
alkenyl
alkynyl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180034394.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102985420A (zh
Inventor
B·潘尼克
L·J·W·M·欧冷
J·G·塔朗特
D·S·林
X·朱
D·郑
R·K·米什拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of CN102985420A publication Critical patent/CN102985420A/zh
Application granted granted Critical
Publication of CN102985420B publication Critical patent/CN102985420B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
CN201180034394.7A 2010-06-01 2011-06-01 细胞色素p450抑制剂及其用途 Expired - Fee Related CN102985420B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39669610P 2010-06-01 2010-06-01
US61/396,696 2010-06-01
US201061460243P 2010-12-29 2010-12-29
US61/460,243 2010-12-29
PCT/US2011/038695 WO2011153192A2 (en) 2010-06-01 2011-06-01 Cytochrome p450 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CN102985420A CN102985420A (zh) 2013-03-20
CN102985420B true CN102985420B (zh) 2017-07-04

Family

ID=45067258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180034394.7A Expired - Fee Related CN102985420B (zh) 2010-06-01 2011-06-01 细胞色素p450抑制剂及其用途

Country Status (8)

Country Link
US (3) US8513291B2 (https=)
EP (1) EP2576544A4 (https=)
JP (1) JP6088425B2 (https=)
CN (1) CN102985420B (https=)
AU (1) AU2011261586B2 (https=)
CA (1) CA2800664C (https=)
IL (1) IL223056A (https=)
WO (1) WO2011153192A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
EP2760854B1 (en) * 2011-09-30 2017-08-30 Asana BioSciences, LLC Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
RS54936B1 (sr) 2011-10-14 2016-11-30 Ambit Biosciences Corp Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
WO2014093960A1 (en) * 2012-12-16 2014-06-19 Angion Biomedica Corp. Compositions and methods for treating disease
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
JP7160487B2 (ja) 2017-05-04 2022-10-25 ビーエーエスエフ ソシエタス・ヨーロピア 植物病原菌を駆除するための置換５－（ハロアルキル）－５－ヒドロキシ－イソオキサゾール

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000311A1 (en) * 2003-06-24 2005-01-06 Glaxo Group Limited Substituted diketopiperazines for the treatment of benign prostatic hyperplasia
CN1604803A (zh) * 2001-12-12 2005-04-06 泰博特克药品有限公司 细胞色素p450依赖性蛋白酶抑制剂的组合物
US20060111408A1 (en) * 2000-12-22 2006-05-25 Bernard Barlaam Therapeutic benzothiazole compounds
CN1819996A (zh) * 2003-07-10 2006-08-16 Osi制药公司 作为细胞色素p450抑制剂的亚萘基衍生物
US20090054405A1 (en) * 2007-08-02 2009-02-26 Amgen Inc. PI3 kinase modulators and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049704A1 (en) 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
JP2003521543A (ja) * 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
WO2002003912A2 (en) 2000-07-11 2002-01-17 University Of Maryland, Baltimore Novel c-4 substituted retinoids
BRPI0406883A (pt) * 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
BRPI0511257A (pt) * 2004-05-19 2007-11-27 Clariant Finance Bvi Ltd corantes de monoazo em ponte
CA2667453A1 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
US8053574B2 (en) * 2007-07-18 2011-11-08 Novartis Ag Organic compounds
MX2010004246A (es) * 2007-10-18 2010-04-30 Novartis Ag Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas.
WO2010036404A2 (en) 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
GB0811091D0 (en) 2008-06-17 2008-07-23 Cancer Rec Tech Ltd CYP26 Inhibitors
US8987315B2 (en) 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060111408A1 (en) * 2000-12-22 2006-05-25 Bernard Barlaam Therapeutic benzothiazole compounds
CN1604803A (zh) * 2001-12-12 2005-04-06 泰博特克药品有限公司 细胞色素p450依赖性蛋白酶抑制剂的组合物
WO2005000311A1 (en) * 2003-06-24 2005-01-06 Glaxo Group Limited Substituted diketopiperazines for the treatment of benign prostatic hyperplasia
CN1819996A (zh) * 2003-07-10 2006-08-16 Osi制药公司 作为细胞色素p450抑制剂的亚萘基衍生物
US20090054405A1 (en) * 2007-08-02 2009-02-26 Amgen Inc. PI3 kinase modulators and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors;Jie Pan，等;《European Journal of Medicinal Chemistry》;20091126;第45卷(第3期);第967-972页 *
The Development of the Antitumour Benzothiazole Prodrug, Phortress, as a Clinical Candidate;T. D. Bradshaw，等;《Current Medicinal Chemistry》;20040401;第11卷(第8期);第1241-1253页 *

Also Published As

Publication number Publication date
IL223056A0 (en) 2013-02-03
JP2013527238A (ja) 2013-06-27
AU2011261586B2 (en) 2015-08-27
CN102985420A (zh) 2013-03-20
US8865752B2 (en) 2014-10-21
IL223056A (en) 2016-06-30
AU2011261586A1 (en) 2012-12-06
CA2800664C (en) 2019-09-24
US8513291B2 (en) 2013-08-20
WO2011153192A3 (en) 2012-04-19
WO2011153192A2 (en) 2011-12-08
EP2576544A2 (en) 2013-04-10
JP6088425B2 (ja) 2017-03-01
US20130102643A1 (en) 2013-04-25
US20140018401A1 (en) 2014-01-16
US20150158853A1 (en) 2015-06-11
EP2576544A4 (en) 2013-09-11
CA2800664A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
CN102985420B (zh) 细胞色素p450抑制剂及其用途
US20140329871A1 (en) Small molecule anti-fibrotic compounds and uses thereof
US11459319B2 (en) Cytochrome P450 inhibitors and uses thereof
AU2020257075B2 (en) Methods and agents for treating disease
US20210171515A1 (en) Cytochrome p450 inhibitors and uses thereof
US10414760B2 (en) Cytochrome P450 inhibitors and uses thereof
US20160038490A1 (en) Compositions and methods for treating dysproliferative diseases
HK40053175A (en) Cytochrome p450 inhibitors and uses thereof
HK1203502A1 (en) Antifibrotic compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170704